Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by QRG Capital Management Inc.

QRG Capital Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,180 shares of the biopharmaceutical company’s stock after acquiring an additional 1,040 shares during the period. QRG Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $24,368,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of REGN. Asset Management One Co. Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 2.2% in the 3rd quarter. Asset Management One Co. Ltd. now owns 56,476 shares of the biopharmaceutical company’s stock valued at $59,370,000 after purchasing an additional 1,213 shares during the period. National Pension Service lifted its stake in shares of Regeneron Pharmaceuticals by 17.0% in the 3rd quarter. National Pension Service now owns 223,617 shares of the biopharmaceutical company’s stock valued at $235,075,000 after purchasing an additional 32,457 shares during the period. Robeco Institutional Asset Management B.V. lifted its stake in shares of Regeneron Pharmaceuticals by 1.0% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 128,178 shares of the biopharmaceutical company’s stock valued at $134,746,000 after purchasing an additional 1,243 shares during the period. Nvwm LLC increased its holdings in Regeneron Pharmaceuticals by 1.4% in the 3rd quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company’s stock worth $1,039,000 after acquiring an additional 14 shares in the last quarter. Finally, Van ECK Associates Corp increased its holdings in Regeneron Pharmaceuticals by 8.9% in the 3rd quarter. Van ECK Associates Corp now owns 58,136 shares of the biopharmaceutical company’s stock worth $61,115,000 after acquiring an additional 4,742 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday. One analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,097.25.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.2 %

NASDAQ REGN traded up $1.84 during trading hours on Monday, reaching $845.44. The company had a trading volume of 13,466 shares, compared to its average volume of 515,277. The stock has a 50-day moving average of $1,058.43 and a 200 day moving average of $1,040.85. Regeneron Pharmaceuticals, Inc. has a 1-year low of $783.57 and a 1-year high of $1,211.20. The company has a current ratio of 5.99, a quick ratio of 4.62 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $93.20 billion, a P/E ratio of 20.88, a price-to-earnings-growth ratio of 2.88 and a beta of 0.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The business’s quarterly revenue was up 12.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $8.79 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.46 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.